External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

Abstract Background Recent treatment guidelines support the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes and cardiovascular disease based on the results of cardiovascular outcome trials (CVOTs). Applicability of these trials to everyday patients with typ...

Full description

Bibliographic Details
Main Authors: Lisanne C. A. Smidt, Frank L. J. Visseren, Wendela L. de Ranitz-Greven, Hendrik M. Nathoe, L. Jaap Kappelle, Gert J. de Borst, Harold W. de Valk, Jan Westerink, the UCC-SMART Study Group
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Cardiovascular Diabetology
Subjects:
Applicability
Cardiovascular disease
Cardiovascular outcome trial
Sodium-glucose cotransporter 2 inhibitor
Type 2 diabetes
Online Access:https://doi.org/10.1186/s12933-021-01373-9

Internet

https://doi.org/10.1186/s12933-021-01373-9

Similar Items